Walsh | Biopharmaceuticals | Buch | 978-1-394-21112-8 | www.sack.de

Buch, Englisch, 560 Seiten, Format (B × H): 173 mm x 249 mm, Gewicht: 1089 g

Walsh

Biopharmaceuticals

Biochemistry and Biotechnology
3. Auflage 2026
ISBN: 978-1-394-21112-8
Verlag: John Wiley & Sons Inc

Biochemistry and Biotechnology

Buch, Englisch, 560 Seiten, Format (B × H): 173 mm x 249 mm, Gewicht: 1089 g

ISBN: 978-1-394-21112-8
Verlag: John Wiley & Sons Inc


Updated all-in-one guide to understanding the science, development and manufacture of bio-based therapeutics

Biopharmaceuticals: Biochemistry and Biotechnology is a unique resource on biopharmaceuticals that serves as a comprehensive introduction to both the biopharmaceutical industry and its role within the global pharmaceutical industry. This new edition incorporates all major advances from the past 20 years, including the development of biosimilars, bispecific and other engineered antibody formats, engineered cell-based therapies, RNA-based vaccines, and genome editing techniques. Case studies and application examples demonstrate the entire value chain, from development to approval and manufacturing of all types of biopharmaceuticals, covering antibodies (mAbs), cytokines, nucleic acid therapeutics as well as cell-based and other biotherapeutics. Written by an accomplished instructor and textbook writer who has been working with small and large biotech companies for more than 25 years, Biopharmaceuticals: Biochemistry and Biotechnology covers: - Protein structure (covering protein folding, stability, engineering and structure prediction, post-translational modifications) and recombinant production
- Discovery, development and biopharmaceutical regulation
- mAb-based therapeutics and vaccines
- Cytokines and growth factors, including interferons, interleukins, haematopoietic growth factors, and colony stimulating factors (CSFs)
- Recombinant blood products and therapeutic enzymes, covering clotting disorders, anticoagulants, thrombolytic agents, and enzymes of therapeutic value
- Hormones, including insulins, GLP-1 related products, human growth hormone and gonadotropins
- Product manufacture (upstream and downstream processing) and analysis, covering API characterization, purity and potency determinations, analytical methodologies, protein content, and contaminant testing

Delivering comprehensive coverage of the field, Biopharmaceuticals: Biochemistry and Biotechnology is an essential reference for students and professionals in biotechnology, medical biochemistry, medicinal chemistry, and pharmaceutical technology.

Walsh Biopharmaceuticals jetzt bestellen!

Autoren/Hrsg.


Weitere Infos & Material


Preface xiv

1 Biopharmaceuticals, an Introductory Overview 1

1.1 Introduction to Pharmaceutical Products 1

1.2 Genetic Engineering and the Advent of Biopharmaceuticals 7

1.3 Biopharmaceuticals: Current Status and Future Prospects 12

Sources of Additional Information 20

Some Journal Articles 21

2 Biopharmaceuticals: Discovery, Development, and Regulation 23

2.1 Introduction 23

2.2 Discovery of Biopharmaceuticals 24

2.3 The Impact of “Omics” and Related Technologies Upon Drug Discovery 26

2.4 Lead Discovery 34

2.5 Pharmacogenetics 34

2.6 The Influence of Artificial Intelligence Upon Drug Discovery 35

2.7 Lead Characterization, CMC Development, and QbD 36

2.8 Delivery of Biopharmaceuticals 39

2.9 Preclinical Studies 43

2.10 Pharmacokinetics and Pharmacodynamics 43

2.11 Toxicity Studies 50

2.12 Clinical Trials 53

2.13 The Role and Remit of Regulatory Authorities 57

2.14 The Food and Drug Administration (FDA) 58

2.15 European Pharmaceutical Law 61

2.16 Pharmacovigilance 65

2.17 World Harmonization of Drug Regulations and the ICH 66

2.18 The Naming of Biopharmaceuticals 67

2.19 Patenting 68

2.20 Biosimilar Regulation 69

Sources of Additional Information 73

Some Journal Articles 73

3 Good Manufacturing Practice 75

3.1 Introduction 75

3.2 Guides to Good Manufacturing Practice (GMP) 75

3.3 Pharmacopoeia 77

3.4 The Manufacturing Facility 78

3.5 Documentation 93

3.6 Validation 95

Further Reading 97

4 Protein Structure 99

4.1 Introduction 99

4.2 Primary Structure 99

4.3 Higher-Level Structure 106

4.4 Protein Folding and Stability 111

4.5 Protein Structure Prediction 113

4.6 Protein Post-translational Modification 115

Further Reading 123

5 Production of Therapeutic Proteins by Recombinant Means 125

5.1 Introduction 125

5.2 Nucleic Acids: Structure and Function 125

5.3 The Principles of Genetic Engineering 133

5.4 Cell Types in Which Recombinant Therapeutic Proteins Are Produced 147

5.5 Engineered Therapeutic Proteins 159

Further Reading 164

6 Therapeutic Protein Manufacture: Upstream Processing 165

6.1 Introduction 165

6.2 Cell Banking Systems 166

6.3 Bioreactors 168

6.4 Microbial Cell Fermentation 174

6.5 Mammalian Cell Culture 176

Further Reading 180

7 Therapeutic Protein Manufacture: Downstream Processing 181

7.1 Initial Product Recovery 181

7.2 Initial Product Concentration 187

7.3 Chromatographic Purification 190

7.4 Viral Clearance 212

7.5 Some Influences Which can Alter the Biological Activity of Proteins 213

7.6 Final Product Formulation 217

7.7 Sterilization and Final Product Fill 219

7.8 Trends in Downstream Processing 224

Further Reading 225

8 Product Analysis 227

8.1 Introduction and Regulatory Context 227

8.2 Potency Determination 229

8.3 Protein Content 232

8.4 Purity Determination and API Characterization 233

8.5 Key Analytical Methodologies 235

8.6 Product Purity Determination 238

8.7 API Characterization 240

8.8 Non- protein Impurity Characterization: DNA 247

8.9 Contaminant Testing 248

8.10 Additional Tests 255

Further Reading 255

9 Antibodies 257

9.1 Antibody Structure and Function 257

9.2 Polyclonal Antibody Preparations Used Therapeutically 262

9.3 Hybridoma Technology and First- generation Monoclonal Antibodies 265

9.4 Chimeric and Humanized Antibodies 268

9.5 Fully Human mAbs 271

9.6 Routine Manufacture of mAbs 274

9.7 mAb Therapeutic Applications in Overview 275

9.8 mAb Therapeutics Treating Inflammation 275

9.9 mAbs Therapeutic Treating Cancer 277

9.10 Some Additional Therapeutic mAbs 283

9.11 Additional Engineered Antibody Formats 286

9.12 The mAb Market and the Advent of mAb Biosimilars 302

Further Reading 305

10 Vaccines 307

10.1 Introduction 307

10.2 Traditional Vaccine Preparations 309

10.3 The Impact of Recombinant DNA Technology on Vaccines 313

10.4 Adjuvant Technology 332

Further Reading 335

11 The Cytokines – The Interferon Family 337

11.1 Introduction to the Cytokines 337

11.2 The Interferons 344

11.3 Interferon Biotechnology 356

Further Reading 363

12 The Cytokines – Interleukins and Tumor Necrosis Factor 365

12.1 Introduction to the Interleukins 365

12.2 Interleukin- 2 367

12.3 IL- 2 Biotechnology 370

12.4 Interleukin 11 373

12.5 Inhibition of Interleukin Activity 374

12.6 Tumor Necrosis Factor 379

Further Reading 389

13 Growth Factors 391

13.1 Introduction 391

13.2 Hematopoietic Growth Factors 391

13.3 Granulocyte Colony- Stimulating Factor (G- CSF) 394

13.4 Macrophage colony- stimulating factor (M- CSF) 395

13.5 Granulocyte Macrophage Colony- Stimulating Factor (GM- CSF) 395

13.6 Clinical Application of CSFs 396

13.7 Erythropoietin 400

13.8 Therapeutic Applications of EPO 402

13.9 Thrombopoietin 404

13.10 Insulin- Like Growth Factors 407

13.11 Neurotrophic Factors 408

13.12 Fibroblast Growth Factors 410

13.13 Platelet- Derived Growth Factor 411

13.14 Bone Morphogenetic Proteins 412

13.15 Inhibition of Growth Factor Activity 413

Further Reading 419

14 Hormones 421

14.1 Introduction 421

14.2 Insulin 421

14.3 The Insulin Molecule 423

14.4 The Insulin Receptor and Signal Transduction 424

14.5 Insulin Manufacture by Traditional Means 426

14.6 Production of Human Insulin by Recombinant DNA Technology 427

14.7 Formulation of Insulin Products 428

14.8 Engineered Insulins 430

14.9 Glucagon- Like Peptide- 1 (GLP- 1)- Related Products 434

14.10 GLP- 1 Receptor Agonists 436

14.11 Human Growth Hormone 440

14.12 The Gonadotrophins 444

14.13 Medical Applications of Gonadotrophins 451

14.14 Additional Recombinant Hormones Now Approved 455

Further Reading 458

15 Recombinant Blood Products and Therapeutic Enzymes 459

15.1 Introduction 459

15.2 Hemostasis 459

15.3 The Coagulation Pathway 459

15.4 Clotting Disorders 463

15.5 Factor VIII and Hemophilia A 464

15.6 Additional Recombinant Blood Factors 470

15.7 Anticoagulants 473

15.8 Thrombolytic Agents 475

15.9 Enzymes of Therapeutic Value 480

Further Reading 492

16 Nucleic- Acid- Based Products 493

16.1 Introduction 493

16.2 Classical Gene Therapy 494

16.3 Basic Approach to Gene Delivery 495

16.4 Vectors Used in Gene Therapy 499

16.5 Manufacture of Viral Vectors 510

16.6 CAR- T- Based Gene Therapy 518

16.7 Non- viral Vectors 522

16.8 The Impact of CRISPR Technology on Gene Therapy 524

16.9 Antisense Technology, Including siRNA 527

Further Reading 533

Index 535


Gary Walsh is Chair of Industrial Biotechnology at the University of Limerick, Ireland. He has direct industrial experience within the pharmaceutical and diagnostic industries, as well as extensive teaching and research interests in the pharmaceutical and biotechnology arena.



Ihre Fragen, Wünsche oder Anmerkungen
Vorname*
Nachname*
Ihre E-Mail-Adresse*
Kundennr.
Ihre Nachricht*
Lediglich mit * gekennzeichnete Felder sind Pflichtfelder.
Wenn Sie die im Kontaktformular eingegebenen Daten durch Klick auf den nachfolgenden Button übersenden, erklären Sie sich damit einverstanden, dass wir Ihr Angaben für die Beantwortung Ihrer Anfrage verwenden. Selbstverständlich werden Ihre Daten vertraulich behandelt und nicht an Dritte weitergegeben. Sie können der Verwendung Ihrer Daten jederzeit widersprechen. Das Datenhandling bei Sack Fachmedien erklären wir Ihnen in unserer Datenschutzerklärung.